Actio Biosciences Announces First Participant Dosed in Phase 1 Clinical Trial of ABS-1230, a KCNT1 Inhibitor for the Treatment of KCNT1-Related Epilepsy
Plans to expand into Phase 1b proof-of-concept study in patients early 2026 SAN DIEGO–(BUSINESS WIRE)–Actio Biosciences, a clinical-stage…